Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: Results of the OPTIMAX 2 study

Vascular Health and Risk Management

Volumn 4, Issue 2, 2008, Pages 443-451

  Mourad, Jean Jacques ^a   Lameira, Dulce ^a   Guillausseau, Pierre Jean ^b  

^a AVICENNE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antihypertensive efficacy; Combination therapy; Hypertension; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL;

ADJUVANT THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERINDOPRIL; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 44049083287     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ADVANCE Collaborative Group. 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 370:829-40.
2. Ajjan R, Carter AM, Somani R, et al. 2007. Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. J Thromb Haemost, 754-60.
3. Alberti KG, Zimmet P, Shaw J. 2005. Metabolic syndrome - anew worldwide definition. Lancet, 366:1059-62.
4. Alberti KG, Zimmet P. 1998. Definition, diagnosis and classification of diabetes and its complications. Part I: diagnosis and classification of diabetes provisional report of a WHO consultation. Diabet Med, 15:539-53.
5. Asmar RG, London GM, O'Rourke ME, et al. 2001. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension, 38:922-6.
6. Balkau B, Charles MA. 1999. Comments on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. Diabet Med, 16:442-3.
7. Barrios V, Escobar C, Calderon A, et al. 2007. Adequacy of the treatment of hypertensive patients with metabolic syndrome. Med Clin (Barc), 128:647-51.
8. Borch-Johnsen K. 2007. The metabolic syndrome in a global perspective. The public health impact -secondary publication. Dan Med Bull, 54:157-9.
9. Choi KM, Kim SM, Kim YE, et al. 2007. International Diabetes federation. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education program and International Diabetes Federation definitions in the Korean population. Metabolism, 56:552-8.
10. Cuspidi C, Meani S, Valerio C, et al. 2007. Age and target organ damage in essentialhypertension: role of the metabolic syndrome. Am J Hypertens, 20:296-303.
11. Day C. 2007. Metabolic syndrome, or What you will: definition and epidemiology. Diab Vasc Dis Res, 4:32-8.
12. De Jongh RT, Serné EH, Ijzerman RG. 2004. Impaired microvascular function in obesity. Implications for obesity associated microangiopathy, hypertension and insulin resistance. Circulation, 109:2529-35.
13. ESC-ESH. 2007. Guidelines for the Management of Arterial Hypertension. 2007. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens, 25:1105-87.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285:2486-97.
15. Ferrara LA, Cardoni O, Mancini M, et al. 2007b. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens, 21:795-801.
16. Ferrara LA, Guida L, Ferrara F, et al. 2007a. Cardiac structure and function and arterial circulation in hypertensive patients with and without metabolic syndrome. J Hum Hypertens, 21:729-35.
17. Ford ES, Giles WH, Dietz WH. 2002. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA, 287:356-9.
18. Garcia-Puig J, Ruilope LM, Luque M, et al. 2006. AVANT Study Group Investigators. Glucose metabolism in patients with essential hypertension. Am J Med, 119:318-26.
19. Grundy SM, Brewer HB, Cleeman JL, et al. 2004. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/AHA conference on scientific issues related to definitions. Circulation, 109:433-8.
20. Grundy SM, Cleeman JI, Daniels SR, et al. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112:2735-52.
21. Hu G, for the DECODE study. 2004. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med, 164:1066-76.
22. Julius S, Gudbrandsson T, Jamerson K, et al. 1991. The hemodynamic link between insulin resistance and hypertension. J Hypertens, 9:983-6.
23. Kelishadi R, Derakhstan R, Sabet B, et al. 2005. The metabolic syndrome in hypertensive and normotensive subjects: the Isfahan Healthy Heart Programme. Ann Acad Med Singapore, 34:243-9.
24. Kelishadi R. 2007. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev, 29:62-76.
25. Lakka HM, Laaksonnen DE, Lakka TA, et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288:2709-16.
26. Leoncini G, Ratto E, Viazzi F, et al. 2005. Metabolic syndrome is associated with early signs of organ damage in nondiabetic hypertensive patients. J Intern Med, 257:454-60.
27. Leoncini G, Ratto E, Viazzi F, et al. 2007. Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. J Hum Hypertens, 21:802-7.
28. Levy BI, Duriez M, Samuel JL, et al. 2001. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens, 14:7-13.
29. London GM, Asmar RG, O'Rourke M, et al. 2004. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol, 43:92-9.
30. Mitrakou A. 2006. Women's health and the metabolic syndrome. Ann NY Acad Sci, 1092:33-48.
31. Mourad JJ, Hanon O, Deverre JR, et al. 2003. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotens Aldoster Syst, 4:94-5.
32. Mulè G, Cottone S, Nardi E, et al. 2006. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage. Minerva Cardioangiol, 54:173-94.
33. Mulè G, Nardi E, Cottone S, et al. 2005. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med, 257:503-13.
34. Mulè G, Nardi E, Cottone S, et al. 2007. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens, 20:197-203.
35. Navarro J, Redon J, Cea-Calvo L, et al. 2007. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study. Blood Press, 16:20-7.
36. Nilsson PM, Engström G, Hedblad B. 2007. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects. A population-based study comparing three different definitions. Diabet Med, 24:464-72.
37. Qiao Q, Gao W, Zhang L, et al. 2007. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem, 44:232-63.
38. Reaven GM. 1988. Banting lecture 1988: role of insulin resistance in human disease. Diabetes, 37:1595-607.
39. Rodilla E, Gonzalez C, Costa JA, et al. 2007. New definition of metabolic syndrome: does it have the same cardiovascular risk? Rev Clin Esp, 207:69-74.
40. Royer M, Castelo-Branco C, Blümel JE, et al. 2007. The US National Cholesterol Education programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climateric, 10:164-70.
41. Schillaci G, Pirro M, Vando G. 2004. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol, 43:1817-22.
42. Tamaki S, Nakamura Y, Yoshino T, et al. 2006. The association between morning hypertension and metabolic syndrome in hypertensive patients. Hypertens Res, 29:783-8.
43. Tonkin R. 2003. The X factor: obesity and the metabolic syndrome. The Science and Public Affairs Forum. World Health organization (1999) Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance.